Survey
Two Week Delay: Skytrofa Usage Survey
Ticker(s): ASNDSurveyed 20 Pediatric Endocrinologists
How many pediatric growth hormone deficiency patients do you have in your practice?
How would you describe your specialty (pediatrician, endocrinologist, pediatric endocrinologist, etc.)?
Do you currently prescribe or have your prescribed Skytrofa to patients with growth hormone deficiency?
How many patients have you prescribed Skytrofa to ever?
Of those, how many patients are receiving the drug free through Ascendis’s patient access program?
The number of patients I have on Skytrofa has ________ over the last 3 months. Select one. a. Increasedb. Remained the samec. Decreased
The number of patients has increased/decreased by ______ over the last 3 months.
What percent of your patients are on commercial insurance versus government insurance?
How has insurance coverage changed over the past 6 months for Skytrofa? Select one. a. Significantly worsenedb. Slightly worsenedc. Stayed the samed. Slightly improvede. Significantly improved
How many patients do you expect to have on Skytrofa in the next year?By this time next year, I will have_____ patients on Skytrofa.
What percent of your Skytrofa prescriptions are for patients who were previously on daily growth hormone (as opposed to those who are growth-hormone naive)?______ % of my Skytrofa prescriptions are switches from daily growth hormone.
Reimbursement for Skytrofa in growth-hormone naive patients is _______ compared to patients switching from daily injections. Select one. a. Significantly worseb. Slightly worsec. Similar d. Slightly improvede. Significantly improved
Please rank in order the factors most influential in your use of Skytrofa (i.e., 1 is the most influential and 5 is the least influential). a. Superior height improvement over daily growth hormoneb. Non-compliance with daily growth hormone injectionsc. Intolerant to daily injectionsd. Inconvenience of daily injectionse. Reimbursement
What primary reason do you anticipate may prevent patients from going on weekly growth hormone? Please be specific.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
